1Canliez B, Berthe MC, LavoinneA. Brain nateiureticpepride: physiolgical, biolgical, biological and clinical aspects[J]. Ann bilo Clin(Paris), 2005, 63(1):15.
2Ndrepepa G, Braun S, MehilliJ, et al. Plasma levels of N-terminal probrain natriuretic peptide in patients with coronaryartery disease and relation to clinical presmtation, angiographic severity, and left ventricular ejection fraction[ J]. Am J Cardiol,2005,95(5) :553.
3MaMa K, Takayoshi T, Wada A,et al.P;as, a brain natriureticpeptid as a symptomatic left ventridular dysfunction[ J]. Am heart, 1998,135:825.
4Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment oucomes in patiens admitted fordeconpensated heart failure: a pilot study[J] .J Am coil cardiol,2001,37(2)386.
5JunnichiI, MasanoriN, Yun N, et al. Risk strat:ification a combi-nation of cardiac troponin T and brain natriuretic heart failure[J]. AmJ Cardiol, 2002,89(6) :691.
3Tentzeris I, Jail R, Farhan S, et al. Complementary role of copeptin and high-senditivity troponin in predicting outcome in patients with stable chronic hearts failure [ J ]. Clin Endo- crinol Metab,2011,121 : 11 -117.
4Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, et all. Amino- terminal pro-C-type natriuretic peptide is associated with arterial stiffness, endothelial function and early atherosclerosis [J] . A theroscle- rosis, 2010, 211 (2) : 649-655.
